The estimated Net Worth of Robert Andrew Berman is at least $455 Thousand dollars as of 18 May 2021. Mr Berman owns over 3,000 units of Hancock Jaffe Laboratories Inc stock worth over $38,780 and over the last 9 years he sold HJLI stock worth over $0. In addition, he makes $415,808 as CEO & Director at Hancock Jaffe Laboratories Inc.
Mr has made over 3 trades of the Hancock Jaffe Laboratories Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of HJLI stock worth $16,410 on 18 May 2021.
The largest trade he's ever made was buying 21,740 units of Hancock Jaffe Laboratories Inc stock on 12 March 2019 worth over $25,001. On average, Mr trades about 3,860 units every 161 days since 2016. As of 18 May 2021 he still owns at least 3,736 units of Hancock Jaffe Laboratories Inc stock.
You can see the complete history of Mr Berman stock trades at the bottom of the page.
Robert A. Berman is the CEO & Director at Hancock Jaffe Laboratories Inc.
As the CEO & Director of Hancock Jaffe Laboratories Inc, the total compensation of Mr Berman at Hancock Jaffe Laboratories Inc is $415,808. There are no executives at Hancock Jaffe Laboratories Inc getting paid more.
Mr Berman is 57, he's been the CEO & Director of Hancock Jaffe Laboratories Inc since . There are 3 older and no younger executives at Hancock Jaffe Laboratories Inc. The oldest executive at Hancock Jaffe Laboratories Inc is Dr. Marc H. Glickman, 71, who is the Sr. VP & Chief Medical Officer.
Robert's mailing address filed with the SEC is C/O JAFFE LABORATORIES,, 70 DOPPLER, IRVINE, CA, 92618.
Over the last 6 years, insiders at Hancock Jaffe Laboratories Inc have traded over $1,313,267 worth of Hancock Jaffe Laboratories Inc stock and bought 39,132 units worth $123,953 . The most active insiders traders include Holding, S.A. Biodyne, Robert Andrew Berman, and Francis Duhay. On average, Hancock Jaffe Laboratories Inc executives and independent directors trade stock every 100 days with the average trade being worth of $3,344,125. The most recent stock trade was executed by Matthew Jenusaitis on 25 August 2021, trading 1,300 units of HJLI stock currently worth $10,010.
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.
Hancock Jaffe Laboratories Inc executives and other stock owners filed with the SEC include: